IL6 and plasma cell myeloma: In multiple myeloma, the DNA-damaging drug doxorubicin could trigger an ataxia-telangiectasia-mutated (ATM) kinase-dependent DDR in bone marrow stromal cells, leading to increased IL-6 secretion by CAFs and resistance of myeloma cells to doxorubicin-induced apoptosis [71].